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Background: Cardiopulmonary bypass induces a systemic inflammatory response
that may contribute to clinical morbidity. Gaseous nitric oxide at relatively low
concentrations may elicit peripheral anti-inflammatory effects in addition to a
reduction of pulmonary resistances. We examined the effects of 20 ppm of inhaled
nitric oxide administered for 8 hours during and after cardiopulmonary bypass.
Methods and Results: Twenty-nine consecutive patients undergoing aortic valve
replacement combined with aortocoronary bypass were randomly allocated to either
20 ppm of inhaled nitric oxide (n  14) or no additional inhalatory treatment (n 
15). Blood samples for total creatine kinase, creatine kinase MB fraction, and
troponin I measurements were collected at 4, 12, 24, and 48 hours postsurgery. In
addition, we collected perioperative blood samples for measurements of circulating
nitric oxide by-products and brain natriuretic peptide. Soluble P-selectin was ana-
lyzed in blood samples withdrawn from the coronary sinus before and after aortic
clamping. The area under the curve of creatine kinase MB fraction (P  .03), total
creatine kinase (P  .04), and troponin I (P  .04) levels were significantly
decreased in the nitric oxide–treated patients. Moreover, in the same group we
observed blunted P-selectin and brain natriuretic peptide release (P  .01 and P 
.02, respectively). Nitric oxide inhalation consistently enhanced nitric oxide metab-
olite levels (P  .01).
Conclusions: Nitric oxide, when administered as a gas at low concentration, is able
to blunt the release of markers of myocardial injury and to antagonize the left
ventricular subclinical dysfunction during and immediately after cardiopulmonary
bypass. The organ protection could be mediated, at least in part, by its anti-
inflammatory properties.
Many factors during cardiopulmonary bypass (CPB), both ma-terial-dependent and material-independent, have been docu-mented to induce a complex inflammatory response.1 Thisinflammatory cascade may contribute to the development ofpostoperative complications, including respiratory failure, re-nal dysfunction, bleeding disorders, neurologic dysfunction,
altered liver function, myocardial injury, and, finally, multiple organ failure.
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Oxygen-derived free radicals are primarily involved in
ischemia-reperfusion injury, maximally affecting the myo-
cardium at the onset of reperfusion, after release of aortic
clamp.2 Reperfusion injury has a complex pathophysiology.
It develops over a period of several (2-24) hours and in-
volves 2 distinct but related events, coined “the endothelial
trigger” and “the neutrophil amplification” step.3 One of the
major early events leading to endothelial dysfunction is the
loss of the release of nitric oxide (NO) by endothelial cells,
which occurs within a few minutes of reestablishing flow.
This finding has been demonstrated in both an intact animal
subjected to myocardial ischemia-reperfusion and in an
isolated perfused organ (the heart) subjected to reperfusion
with a blood-free solution.4 The endothelial dysfunction is
followed by a sequence of events that results from the
altered status of the endothelium. The second major step in
the process of reperfusion injury is the “neutrophil ampli-
fication step,” which involves leukocyte–endothelial cell
interactions leading to leukocyte adherence to the endothe-
lium and transendothelial migration of neutrophils across
the endothelium.5 There is a dramatic increase in neutrophil
adherence, which reaches its maximum at 20 minutes post-
reperfusion.6 These data strongly implicate the role of ad-
hesion molecule expression and especially of P-selectin,
which are up-regulated within a few minutes.7 This en-
hanced leukocyte adherence to the endothelium leads to
capillary plugging and edema formation, resulting in reduc-
tion of coronary blood flow. The response to ischemia-
reperfusion injury is termed the “no-reflow phenomenon.”8
These events culminate in a profound degree of myocardial
cell necrosis and/or apoptosis at 4 to 24 hours postreperfu-
sion, with early and late reduction of myocardial contrac-
tility.9
Because reduced NO release is proven to be a marked
and early event in the reperfusion injury, we speculated that
NO replacement therapy could blunt the consequences of
ischemia-reperfusion injury. One component of the reduced
NO release is the enhanced quenching of NO by superoxide
radicals, which appears to be related to superoxide radicals
produced by the abrupt reoxygenation of the reperfusion
process.10
The present investigation addresses the beneficial effect
of inhaled NO, administered at pharmacological dosages
(20 ppm) during and for 8 hours after CPB, in minimizing
the release of markers of myocardial injury and left ventric-
ular dysfunction in patients undergoing CPB.
Methods
Study Design
This investigation was designed as a prospective, randomized,
nonblinded study carried out at the Pasquinucci Hospital in Massa,
Italy, between July 2000 and April 2002. After approval of the
Local Ethical Commission, informed consent was obtained from
29 patients undergoing nonemergency aortic valve replacement
combined with aortocoronary bypass, and the patients were en-
rolled in the present study.
Patients with an active infection, ejection fraction 30%, ma-
lignancy, or a history of hematologic, hepatic, or renal disorders
were excluded. Exclusion criteria also included corticosteroid or a
nonsteroidal anti-inflammatory treatment within the previous 7
days or during surgery, or a postoperative treatment with nitrates
or sodium nitroprussiate.
Study Procedures
All potential patients were screened before enrollment. When all
inclusion and exclusion criteria were satisfied, patients were ran-
domized. Perioperative testing included medical history and phys-
ical examination, laboratory testing (hematology, chemistry, and
urinalysis), electrocardiogram, and echocardiography. Demo-
graphic characteristics and surgical data are reported in Table 1.
Surgical Protocol
The surgical protocol consisted of conventional median sternot-
omy access and the institution of CPB using a double-stage venous
cannula in the right atrium and an arterial cannula in the ascending
aorta. All procedures were performed in mild hypothermia (32-
35°C), using retrograde, intermittent, hematic hyperkalemic car-
dioplegic solution through the coronary sinus.
NO Delivery, Systems, and Timing
NO gas was mixed with nitrogen (500 ppm). The mixture of gases
was continuously introduced into the patient’s ventilatory circuit
and was connected to a time-cycled anesthesia machine ventilator
(Servo 900D; Siemens-Elema, Stockholm, Sweden). The NO gas
inlet was proximally connected to the inspiratory part of the patient
ventilatory circuit. The concentration of NO delivered was side-
stream analyzed by a chemiluminescent instrument (Nox Box
Bedfont Scientific, Kent, United Kingdom) connected to the distal
inspiratory limb of the ventilatory circuit. The exhaled gas and
TABLE 1. Demographic, clinical, and surgical characteris-
tics
Parameter
NO group
(n  14)
Control group
(n  15)
Age (years) 70 13 69 10
Gender (number of men) 9 8
Current smokers 5 5
Arterial hypertension 8 9
Creatininemia (mg/dL) 1.2 0.5 1.1 0.7
Triglycerides (mg/dL) 128 41 133 53
LDL cholesterol (mg/dL) 106 40 102 35
Type-2 diabetes 3 4
Number of coronary artery disease 2 1.0 2 0.9
Parsonnet index (23) 3 1.2 2.6 0.8
Preoperative ejection fraction (%) 57 9 54 9
Time of extracorporeal circulation
(min)
107 40 110 35
Time of aortic clampage (min) 76 12 78 16
Time of intubation (h) 14 6 14 5
Time in intensive care unit (h) 35 21 35 16
LDL, Low-density lipoprotein; NO, nitric oxide.
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gases exiting the chemiluminescence instrument were collected
into a Venturi device (Servo 900D; Siemens-Elema, Stockholm,
Sweden) and discharged into the hospital vacuum system. At the
onset of CPB (when 100% oxygen is usually delivered to the
membrane oxygenator), NO was delivered to the oxygenator with
our hospital’s standardized oxygen/air mixture flow into the side
port of the inlet gas tubing, close to the flowmeters. The cardiople-
gic solution circuit was designed to administer oxygenated hy-
perkalemic blood enriched with NO. The NO analyzing instrument
was connected at the distal part of the gas tubing, close to the
oxygenator. The delivery of NO was adjusted using a flowmeter on
the cylinder manifold to provide a constant preset concentration of
NO. The fine-tuning of the NO concentration delivered was cor-
rected on the basis of the chemiluminescent analysis. The NO was
administered to each patient during the entire period of intubation,
from the operating theater to the intensive care unit. In particular,
NO delivery was started immediately after patient intubation in the
operating theater via the ventilatory circuit, then continued
throughout the CPB directly into the pump prime and in the
intensive care unit via the ventilator circuits until suspension of
mechanical ventilation. The gas outflow from the membrane oxy-
genator was scavenged using the wall-mounted vacuum system.
During inhalation, hemodynamic variables were monitored by
routine cardiac catheterization. A standard blood gas analyzer was
used to measure PaO2, PaCO2, and pH.
Blood Sample Collection
Blood samples for indices of myocardial injury were drawn before
surgery and 4, 12, 24, and 48 hours after surgery. NO by-products
were measured in blood samples taken prethoracotomy (before
heparinization), 5 minutes post–aortic clamping, 5 minutes post–
aortic unclamping, and 24 hours postsurgery, approximately 12
hours after NO was stopped. Analogously, for brain natriuretic
peptide (BNP) measurements we used peripheral blood samples
drawn prethoracotomy (before heparinization), 5 minutes post–
aortic clamping, 5 minutes post–aortic unclamping, 5 minutes
post-CPB, and 4 and 24 hours postsurgery. Blood samples from
coronary sinus were taken before and after cardioplegia for P-
selectin measurements. All samples were immediately centrifuged
at 4°C and stored at 80°C until they were assayed.
Biological Assays
Soluble P-selectin was measured by a double sandwich enzyme-
linked immunosorbent assay (Bender, Vienna, Austria) in hepa-
rinized plasma samples.11 Assays were performed in duplicate on
duplicate samples, each assayed at least at 2 different dilutions.
Values obtained in healthy people ranged between 100 and 300
ng/mL, in accordance with the literature.11 Plasma BNP was
measured by a noncompetitive immunofluorometric assay (Triage
BNP Test, Biosite Diagnostics, Inc, San Diego, Calif), as described
elsewhere.12 The imprecision of the Triage method was about 12%
for BNP concentrations in the normal range and about 18% for
BNP concentrations above the normal range. The working range
was 5 to 1300 pg/mL.
Measurements of NO Metabolites
To analyze the NO metabolites (NOx), the plasma samples were
ultrafiltered through 30-KDa molecular weight cutoff filters and
centrifuged at 1000g for 60 minutes to remove hemoglobin, which
is known to interfere with subsequent spectrophotometric mea-
surements. Afterward, NOx concentration was determined by a
colorimetric assay kit (Cayman, Ann Arbor, Mich) based on Griess
reaction.13 Standards for calibration curves were prepared with
nitrate and taken through the full assay procedure. The results were
expressed as mol/L of NOx.
Creatine Kinase-MB and Troponin I Assay
Myocardial-specific isoforms of creatine kinase (CK) and troponin
I were measured in our clinical laboratory by a point-of-care
immunometric technique (Triage cardiac panel kit).
Statistical Analysis
All data are presented as mean  standard error of the mean
(SEM). Statistical analysis was performed by multivariate analysis
of variance for repeated measurements for a comparison among
more than 2 groups and Student t test for a comparison between 2
groups; correlation among variables was estimated by a linear
regression analysis with the aid of the Statview statistical package
(Abacus Concepts, Inc, Berkeley, Calif).
Results
Population Characteristics
Demographic variables, chemistry laboratory values, and
surgical parameters (Table 1) did not significantly differ
between the 2 patient groups.
NO By-product Measurements
Measurements of NO metabolites showed significant intra-
and intergroup differences: in the NO group the peak level
was observed at time T1, corresponding to the intraopera-
tory sample, before thoracotomy, 10 minutes after starting
NO inhalation (Figure 1). NO metabolites continued to
exhibit significantly higher levels compared with basal val-
Figure 1. Results of colorimetric assay for NO by-products (NO2
and NO3) on blood samples peripherally drawn at prefixed
perioperative intervals: T1, prethoracotomy; T2, 5 minutes after
aortic clamping; T3, 5 minutes after aortic unclamping; T4, 24
hours after surgery. Data shown are mean  SEM for patients
who received NO (lighter blocks) and for controls (darker blocks).
*P < .05.
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ues (P  .02) at 5 minutes post–aortic clamping (T2) and 5
minutes post–aortic unclamping (T3), corresponding to the
extracorporeal circulation period, when NO was adminis-
tered in the membrane oxygenator as described. At time T4,
24 hours after surgery and about 12 hours after stopping NO
inhalation, NO by-products completely reverted to basal
levels. In the control group we did not observe a significant
increase in NO by-products during the extracorporeal cir-
culation period compared with basal values. Overall com-
parison between NO and control groups indicated a statis-
tically significant difference (P  .01).
Analysis of Myocardial Injury
Indices of myocardial injury showed a constant increase
throughout the first 24 hours after surgery (Figure 2). Com-
parison between groups for total CK release indicated a
statistically significant difference at 24 and 48 hours (P 
.02; Figure 2, A) and for the cumulative release summarized
by the area under the curve (AUC; P  .04; Figure 2, B).
Analogously, we found the peak levels of creatine kinase
MB fraction (CK-MB) at 24 hours (P  .01); values at 48
hours (P  .01; Figure 2, C) and the AUC (P  .03; Figure
2, D) were significantly lower in the NO group as compared
with the control group. Moreover, in the same group the
AUC of troponin I was lower than in the control group (P
.04; Figure 3).
Analysis of Endothelial Cell Activation
In both groups we observed a relevant increase of soluble
P-selectin in plasma samples collected from coronary sinus
immediately before and after aortic clamping (Figure 4, A).
The amount of this inflammatory release, which was also
calculated as a pre–/post–aortic clampage gradient (Figure
4, B), turned out to be significantly blunted in the NO group
as compared with the control group (P  .02).
Analysis of Left Ventricular Dysfunction
To normalize the basal values (T1), we analyzed the gradi-
ent of BNP release as measured by the percent of the ratio
between the levels at each time (T2-T6) compared with T1
(Figure 5). We observed a statistically significant difference
at T5 (P  .02), with lower levels (249  71 vs 311  141
pg/mL) in the NO group.
Discussion
Effective inhibition of CPB-induced inflammatory reaction
and of ischemia-reperfusion injury following coronary ar-
tery bypass surgery has the potential to significantly reduce
clinical morbidity.14 These phenomena are both present in
patients undergoing aortic valve replacement and coronary
artery bypass revascularization.
We report that administration of NO via inhalation im-
mediately before, during, and after surgery may positively
Figure 2. Analysis of myocardial injury determined in CPB pa-
tients by measurements of the release of total CK (A) and CK-MB
(C) and by measurements of the cumulative release (AUC) of total
CK (B) and CK-MB (D) over 48 hours postsurgery. Data shown are
mean  SEM for patients who received NO (lighter blocks) and
for controls (darker blocks). *P < .05.
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affect the pattern of release of markers of myocardial injury
and left ventricular dysfunction, independently on its hemo-
dynamic effects on the pulmonary vasculature and arterial
saturation.
A major pathophysiological clue of the post-CPB reac-
tion is an overall decrease of the endothelial NO synthase,
responsible for a deficient vasodilatory tendency of the
microvasculature and for an increased permeability of the
endothelium toward circulating leukocytes.15 As a conse-
quence, an inflammatory infiltration spreads out inside pe-
ripheral tissues, releasing toxic mediators that further am-
plify the inflammatory reaction and cause organ injury.16 In
this context, restoring NO production is theoretically bene-
ficial. NO inhalation is an alternative route of administration
of NO, with peculiarities that can account for specific ad-
vantages versus other approaches. NO easily diffuses
through the air–blood barrier into the pulmonary circula-
tion. NO inhalation in a low dosage causes selective pul-
monary vasodilation.17 In this district NO diffuses into the
smooth muscle cells, increasing cyclic guanylate mono-
phosphate (cGMP) concentrations, whereas it does not
cause systemic hypotension, being quickly inactivated by
avid binding to hemoglobin.18 In addition to these proper-
Figure 6. Simple regression analysis relating the extent of myo-
cardial injury as detected by the AUC of CK-MB to the gradient of
soluble P-selectin before/after aortic clamping.
Figure 3. Analysis of myocardial injury determined in CPB pa-
tients by measurements of the release of total troponin I over 48
hours postsurgery. Data shown are mean SEM for patients who
received NO (lighter blocks) and for controls (darker blocks). *P
< .05.
Figure 4. Analysis of early endothelial activation in CPB patients
by measurements of soluble P-selectin in blood samples taken
from coronary sinus before and 5 minutes after the end of aortic
clamping (A). Gradient of soluble P-selectin between pre–/post–
aortic clamping in both patients groups are illustrated (B). Data
shown are mean SEM for P-selectin measurements for patients
who received NO (lighter blocks) and for controls (darker blocks).
*P < .05.
Figure 5. BNP release in blood samples peripherally drawn at
prefixed perioperative intervals: T1, prethoracotomy; T2, 5 min-
utes after aortic clamping; T3, 5 minutes after aortic unclamping;
T4, 5 minutes after extracorporeal circulation; T5, 6 hours after
surgery; T6, 24 hours after surgery. To normalize the basal values,
we report the gradient of BNP release as measured by the
percent of the ratio between the levels at each time (T2-T6)
compared with T1. Data shown are mean SEM for patients who
received NO (lighter blocks) and for controls (darker blocks). *P
< .05.
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ties, inhaled NO can mediate some anti-inflammatory ef-
fects directly on the circulating leukocytes and platelets. In
fact, NO gas inhibits human platelet aggregation, P-selectin
expression, and fibrinogen binding in vitro and in vivo.19 If
the concentration of inhaled NO in the inspiratory gas is
below 80 ppm we do not expect pro-oxidant effects.20
Interestingly, NO donors have variable rates of NO release
and some of these substances release different molecules,
with potential collateral effects.21
By measuring NO by-products in peripheral plasma sam-
ples we were able to document a significant increase during
NO therapy beginning with the ventilatory phase and con-
tinuing throughout the extracorporeal circulation (T2 and
T3), although at a lower rate. As we measured peak levels
at time T1, just 10 to 15 minutes after starting inhalation, we
confirmed the fast action of inhaled NO provided by this
route of administration. Lower levels at T2 and T3 as
compared with T1 indicated a less efficient diffusion of NO
through the membrane oxygenator as compared with its
diffusion across the alveolar–blood barrier. Whether the
NO blood concentrations during this phase were adequate or
not is a matter needing further investigation; neither is there
a clear-cut idea about the possible correlation between NO
by-products levels and clinical outcome.
At 20 ppm of inhaled NO we failed to observe any
effects on peripheral vascular resistance, whereas the pul-
monary vascular resistance was significantly decreased, as
expected (75  8 vs 125  16 dynes · s/cm5, P  .002).
Moreover, NO and control groups showed comparable re-
sults in term of arterial oxygen saturation and arterial ten-
sion of oxygen, time of intubation, time in intensive care
unit, and postoperative ejection fraction (data not shown).
Even in a relatively small number of patients we report a
significant protection against perioperative release of mark-
ers of myocardial injury, as indicated by the overall reduced
amounts of total CK, CK-MB, and troponin I levels
throughout the first 24 hours after surgery. This effect was
more impressive in patients with a lower release of soluble
P-selectin in the coronary sinus, measured by the pre-/
postcardioplegia gradient, as shown by the correlation be-
tween the total amount of CK-MB release and the soluble
P-selectin gradient in the local circulation (Figure 6).
This observation, even if it cannot be interpreted as a
definitive explanation of the NO biological action, may
suggest the hypothesis that NO supplementation in the local
circulation, by providing NO directly in the cardioplegic
solution, has a significant anti-inflammatory effect, per se,
cardioprotective.
This finding is just a preliminary report suggesting a
potential therapeutic effect of supplemental NO adminis-
tered before, during, and after CPB. Already some evidence
of the beneficial properties of inhaled NO on ischemia-
reperfusion injury are available in animal models. In 1996 in
a canine model of platelet-mediated reocclusion after
thrombolysis, inhaled NO improved the coronary artery
patency rate.22
Moreover, the observation in the NO group of lower
levels of BNP release, a surrogate of early left ventricular
dysfunction as recently suggested by the European Task
Force for the Diagnosis and Treatment of Heart Failure24
(Figure 5), supports the hypothesis of a real cardioprotective
effect of the NO supplementation. Because the cardioplegic
circuit was designed to administer oxygenated hyperkale-
mic blood enriched with NO, thus delivering the same
amount of NO as the peripheral blood circulating in the
extracorporeal circuit, this method of administration may be
the best access route of therapeutic NO. In fact, whereas the
pulmonary inhaled NO is almost completely metabolized
before reaching the left atrium, NO supplemented in the
cardioplegic solution directly diffuses in the coronary cir-
culation and may elicit a local therapeutic effect.
Limitations of the Study
Several points regarding the effect of supplemented NO are
lacking and need further investigation, such as the optimal
duration of NO treatment, a dose titration of inhaled NO, a
time course of NO by-products to establish how long-lasting
the effect is, and how soon after stopping NO inhalation the
rate of NO by-products falls.
Moreover, the inclusion of patients with combined cor-
onary artery disease could actually add a confounding vari-
able in our analysis; however, major surgical parameters in
the 2 randomized groups were equivalent, including coro-
nary artery disease, the time of CPB, and the time of aortic
clamping (Table 1). Finally, our study had a short follow-
up, limited to the in-hospital period, and was lacking of
major clinical end points that could support the cardiopro-
tective effect of NO. This work is just a pilot and observa-
tional study, based on data of biochemical markers of myo-
cardial injury and left ventricular dysfunction, and requires
confirmation by a larger interventional study to verify the
opportunity to extend the use of NO in clinical settings
involving ischemia-reperfusion damage.
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